Oncobiologics Announces Two New Agreements Worth Almost $80 Million
Oncobiologics recently announced it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US-based large pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies. The identity of the client firm was not disclosed due to confidentiality terms in the agreement. The combined value of the agreements to Oncobiologics totals close to $80 million.
“We are very excited about this agreement with Oncobiologics,” said Dennis O’Donnell, CEO of Parilis Biopharmaceuticals. “This is a major step for Parilis in selecting a biotherapeutic candidate with very high potential. Oncobiologics’ capabilities will enhance our speed to market and provide a much greater chance for success. Oncobiologics gives us access to a team of senior scientists with decades of large pharma experience. We have every confidence that they have the knowledge and scientific rigor needed to help ensure our mutual success.”
“These programs represent a significant milestone for Oncobiologics,” added Jeremy Caudill, Oncobiologics Vice President of Business Development. “They are a validation of our dual strategies; as a fully integrated biopharmaceutical company, as well as providing world-class proof-of-concept services to customers and partners. These agreements also recognize the strength and depth of the team assembled here at Oncobiologics. For a major pharmaceutical organization to entrust an important technical program of this scope reflects the confidence they have in our capabilities. Likewise, Dennis O’Donnell brings a track-record of successes and has chosen Oncobiologics largely on the strength of our team.”
Headquartered in
Total Page Views: 888
